BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst is no longer a typical pre-revenue biotech: audited FY2025 showed $874.8M revenue and $347.4M of operating cash flow, while the Q2 2026 filing shows ~$352.6M of cash + short-term investments and a current ratio around 2.3. Valuation looks inexpensive versus the most recent audited earnings/cash flow, but investors are taking on ORLADEYO concentration/patent risk plus meaningful term-loan and royalty-financing obligations (equity remains negative post-acquisition). Discounted-cash-flow and other market-sentiment fields could not be retrieved in this run and are therefore zeroed.

Dominant catalyst: Japan MHLW approval of pediatric ORLADEYO (regulatory, announced, 2026-08-25, still partially priced), with media sentiment improving determinately from a near-neutral baseline (polarity ≈ −0.01) to a bullish scoring window (≈ +0.30) on profitability, rare-disease M&A intent, and rumored big-pharma suitor interest; the Red-Flag Screen is clean and no cap applies, but with the rewarded catalyst trailing and no forward-dated confirmed event the read is a constructive mixed/forming setup rather than a top-band actionable one.

BCRX is in a persistent short-term downtrend: price 8.43 sits below SMA20 (9.36), SMA50 (9.53), EMA9 (8.69) and EMA21 (9.13), and MACD is deeply negative (line -0.37, signal -0.19, histogram -0.18). ADX14 (23.03) is rising while price is below the entire near-term moving-average stack - trend strength is building on the DOWN side. RSI14 (36.98) is recovering from oversold (29.8 on Sep 11) and today's +3.3% bounce closed near the high of day (8.43 vs 8.33 VWAP), but momentum has not turned (MACD < 0) and price remains below its trend stack. This is a bounce inside a downtrend, not a confirmed reversal. The only candidate setup (oversold-reversal/pullback limit near the 8.02-8.11 support zone) is countertrend per the trend-alignment gate (price < SMA50 with MACD < 0). technicalScore 2 (weak bearish / bounce-only) is below the 3 required for any bullish entry.